Afrezza inhaled insulin: The fastest-acting FDA-approved insulin on the market has favorable properties

Journal of Diabetes Science and Technology

Volumn 8, Issue 6, 2014, Pages 1071-1073

  Klonoff, David C ^a  

^a Mills Peninsula Health Services   (United States)

Author keywords

Afrezza; Diabetes; Inhaled insulin; Pulmonary

Indexed keywords

EXCIPIENT; FUMARYL DIKETOPIPERAZINE; GLUCOSE; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; PIPERAZINEDIONE; RECOMBINANT HUMAN INSULIN; SHORT ACTING INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; INSULIN;

ASTHMA; BRONCHOSPASM; CANCER INCIDENCE; CANCER MORTALITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DIABETES MELLITUS; DRUG ABSORPTION; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GLUCOSE INFUSION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG CANCER; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOLOGICAL PARAMETERS; POWDER INHALER; REVIEW; SMOKING; SORE THROAT; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; DRUG APPROVAL; INHALATIONAL DRUG ADMINISTRATION; UNITED STATES;

ADMINISTRATION, INHALATION; DIABETES MELLITUS; DRUG APPROVAL; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84930740689     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296814555820     Document Type: Review

References (7)

1. FDA approves Afrezza to treat diabetes. June 30, 2014. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm403122.htm. Accessed September 1, 2014.
2. Briefing document. Endocrinologic and metabolic drug advisory committee April 1, 2014. NDA 022472 Afrezza (insulin human [rDNA origin]) inhalation powder. An ultra-rapid acting insulin treatment to improve glycemic control in adult patients with diabetes mellitus. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm390865.pdf. Accessed September 1, 2014.
3. FDA briefing document. Endocrinologic and metabolic drugs advisory committee meeting. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM390864.pdf. Accessed September 1, 2014.
4. Afrezza prescribing information. Available at: http://www.mannkindcorp.com/Collateral/Documents/English-US/Afrez-za-PrescribingInformation.pdf. Accessed September 1, 2014.
5. American Lung Association. Lung cancer fact sheet. Available at: http://www.lung.org/lung-disease/lung-cancer/resources/factsfigures/lung-cancer-fact-sheet.html. Accessed September 1, 2014.
6. Sanofi to pay MannKind up to $925m for inhaled insulin. August 11, 2014. Available at: http://www.lung.org/lung-disease/lungcancer/resources/facts-figures/lung-cancer-fact-sheet.html. Accessed September 1, 2014.
7. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice-daily biaspart insulin for type 2 diabetes: a multicentre randomized trial. Lancet. 2010;375:2244-2253.